Free Trial

Healthcare and Medical Stocks List

This page shows information about the 50 largest healthcare and medical sector stocks including Eli Lilly and Company, Johnson & Johnson, Novo Nordisk A/S and AbbVie. Learn more about health care stocks.

Eli Lilly and Company stock logo

1. Eli Lilly and Company NYSE:LLY

$807.97 +0.78 (+0.10%)
Closing price 03:59 PM Eastern
Extended Trading
$806.50 -1.47 (-0.18%)
As of 05:24 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity. More about Eli Lilly and Company

Pros of Eli Lilly and Company

  • The company has shown impressive revenue growth, with a significant year-over-year increase, indicating strong demand for its products.
  • Eli Lilly and Co has a high return on equity, suggesting effective management and profitability, which can be attractive to investors looking for solid financial performance.
  • The current stock price is around $1,050, reflecting a strong market position and investor confidence in the company's future prospects.

Cons of Eli Lilly and Company

  • The company reported earnings per share that missed consensus estimates, which may raise concerns about its short-term performance and ability to meet investor expectations.
  • There has been a recent downgrade in ratings from some analysts, indicating mixed sentiments about the stock's future performance.
  • The debt-to-equity ratio is relatively high, suggesting that the company relies significantly on debt financing, which can pose risks in a rising interest rate environment.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$765.74 billion
P/E Ratio
69.00
Consensus Rating
Moderate Buy
Consensus Price Target
$1,011.37 (+25.2% Upside)
Volume
3.12 million shares
Average Volume
3.65 million shares
Today's Range
$805.03
$820.72
50-Day Range
$713.99
$899.78
52-Week Range
$677.09
$972.53
Dividend Yield
0.78%
Johnson & Johnson stock logo

2. Johnson & Johnson NYSE:JNJ

$155.19 -1.26 (-0.80%)
Closing price 03:59 PM Eastern
Extended Trading
$155.15 -0.04 (-0.03%)
As of 05:24 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. More about Johnson & Johnson

Pros of Johnson & Johnson

  • The current stock price is around $155, which may present a buying opportunity for investors looking for value in a well-established company.
  • Johnson & Johnson has a strong market capitalization of approximately $373 billion, indicating its stability and ability to weather economic fluctuations.
  • Recent analyst ratings show a consensus of "Moderate Buy," with several analysts issuing price targets above the current stock price, suggesting potential for growth.

Cons of Johnson & Johnson

  • Recent downgrades from analysts, including a reduction in price targets, may indicate concerns about the company's short-term performance.
  • Johnson & Johnson has faced legal challenges and regulatory scrutiny, which could impact its reputation and financial performance.
  • The stock has shown volatility, with a 1-year low of around $140, suggesting potential risks for investors looking for stable returns.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$373.41 billion
P/E Ratio
23.34
Consensus Rating
Moderate Buy
Consensus Price Target
$170.88 (+10.1% Upside)
Volume
6.01 million shares
Average Volume
7.94 million shares
Today's Range
$154.73
$156.60
50-Day Range
$146.39
$157.68
52-Week Range
$140.68
$169.99
Dividend Yield
3.35%
Novo Nordisk A/S stock logo

3. Novo Nordisk A/S NYSE:NVO

$78.66 -0.67 (-0.84%)
Closing price 03:59 PM Eastern
Extended Trading
$78.66 0.00 (0.00%)
As of 05:25 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. More about Novo Nordisk A/S

Pros of Novo Nordisk A/S

  • The current stock price is around $74.70, reflecting a recent increase of 2.8%, which may indicate positive market sentiment.
  • Recent earnings reports show that Novo Nordisk achieved earnings per share of $0.92, meeting consensus estimates, which suggests strong financial performance.
  • The company has a high return on equity of 84.68%, indicating effective management and profitability relative to shareholder equity.

Cons of Novo Nordisk A/S

  • The company has a current ratio of 0.74, which is below the ideal benchmark of 1, indicating potential liquidity issues in meeting short-term obligations.
  • Analysts have mixed ratings, with some downgrading the stock from "strong-buy" to "hold," which may reflect concerns about future growth potential.
  • The stock has a P/E ratio of 22.71, which could be considered high compared to industry averages, suggesting that the stock may be overvalued.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$353.00 billion
P/E Ratio
23.91
Consensus Rating
Hold
Consensus Price Target
$112.00 (+42.4% Upside)
Volume
9.20 million shares
Average Volume
6.97 million shares
Today's Range
$78.34
$79.83
50-Day Range
$57.99
$79.39
52-Week Range
$57.00
$148.15
Dividend Yield
2.25%
AbbVie stock logo

4. AbbVie NYSE:ABBV

$191.27 +1.77 (+0.93%)
Closing price 03:59 PM Eastern
Extended Trading
$191.12 -0.15 (-0.08%)
As of 05:24 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

AbbVie Inc discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn's disease; Rinvoq to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, ulcerative colitis, and Crohn's disease; Imbruvica for the treatment of adult patients with blood cancers; Epkinly to treat lymphoma; Elahere to treat cancer; and Venclexta/Venclyxto to treat blood cancers. More about AbbVie

Pros of AbbVie

  • The current stock price is around $189.89, reflecting a recent increase, which may indicate positive market sentiment towards AbbVie.
  • AbbVie has a strong market capitalization of approximately $335.42 billion, suggesting a solid financial foundation and stability in the market.
  • Institutional investors own over 70% of AbbVie’s stock, indicating confidence from large financial entities in the company's future performance.

Cons of AbbVie

  • Despite its strong market position, AbbVie has a high P/E ratio of 79.12, which may suggest that the stock is overvalued compared to its earnings.
  • The company has a relatively low quick ratio of 0.55, indicating potential liquidity issues that could affect its ability to meet short-term obligations.
  • Recent insider sales, including a significant transaction by an executive vice president, may raise concerns about the company's future performance and insider confidence.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$337.86 billion
P/E Ratio
79.70
Consensus Rating
Moderate Buy
Consensus Price Target
$211.29 (+10.5% Upside)
Volume
3.91 million shares
Average Volume
6.22 million shares
Today's Range
$189.06
$192.72
50-Day Range
$170.01
$198.62
52-Week Range
$163.52
$218.66
Dividend Yield
3.50%
UnitedHealth Group stock logo

5. UnitedHealth Group NYSE:UNH

$310.70 +6.91 (+2.27%)
Closing price 03:59 PM Eastern
Extended Trading
$310.03 -0.67 (-0.22%)
As of 05:24 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

UnitedHealth Group Incorporated operates as a diversified health care company in the United States. The company operates through four segments: UnitedHealthcare, Optum Health, Optum Insight, and Optum Rx. More about UnitedHealth Group

Pros of UnitedHealth Group

  • The current stock price is around $428, which reflects a significant potential for growth based on analyst ratings.
  • UnitedHealth Group has a strong dividend yield of approximately 2.92%, providing investors with a steady income stream.
  • The company has a low payout ratio of 37.02%, indicating that it retains a substantial portion of its earnings for reinvestment and growth.

Cons of UnitedHealth Group

  • Several analysts have downgraded their ratings recently, indicating a shift in market sentiment towards caution.
  • Price targets have been significantly reduced by multiple analysts, suggesting that expectations for future growth may be tempered.
  • There is a notable level of uncertainty in the healthcare sector, which could impact UnitedHealth Group's performance.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$281.85 billion
P/E Ratio
20.05
Consensus Rating
Moderate Buy
Consensus Price Target
$426.52 (+37.3% Upside)
Volume
14.66 million shares
Average Volume
7.09 million shares
Today's Range
$302.23
$311.58
50-Day Range
$273.96
$599.10
52-Week Range
$248.88
$630.73
Dividend Yield
2.77%
Novartis stock logo

6. Novartis NYSE:NVS

$117.99 -0.59 (-0.50%)
Closing price 03:59 PM Eastern
Extended Trading
$118.02 +0.03 (+0.02%)
As of 05:15 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Novartis AG engages in the research, development, manufacture, and marketing of healthcare products in Switzerland and internationally. More about Novartis

Pros of Novartis

  • The current stock price is around $116, which is relatively stable and shows potential for growth given the average price target of $123.38.
  • Novartis AG reported a strong quarterly earnings performance, with earnings per share (EPS) of $2.28, exceeding analyst expectations, indicating robust financial health.
  • The company has demonstrated significant revenue growth, with a year-over-year increase of 11.9%, suggesting effective business strategies and product demand.

Cons of Novartis

  • The stock has a consensus rating of "Hold," which may suggest that analysts are not overly optimistic about its short-term performance.
  • Despite recent revenue growth, the company faces competitive pressures in the pharmaceutical industry, which could impact future earnings.
  • Novartis AG has a relatively low beta of 0.60, indicating less volatility compared to the market, which may not appeal to investors seeking high-risk, high-reward opportunities.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$249.24 billion
P/E Ratio
20.07
Consensus Rating
Hold
Consensus Price Target
$123.38 (+4.6% Upside)
Volume
1.10 million shares
Average Volume
1.59 million shares
Today's Range
$117.71
$118.76
50-Day Range
$101.80
$118.59
52-Week Range
$96.06
$120.92
Dividend Yield
2.20%
Abbott Laboratories stock logo

7. Abbott Laboratories NYSE:ABT

$134.88 +0.75 (+0.56%)
Closing price 03:59 PM Eastern
Extended Trading
$135.00 +0.12 (+0.09%)
As of 05:24 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. More about Abbott Laboratories

Pros of Abbott Laboratories

  • The current stock price is around $129.66, which reflects a strong performance in the market and may indicate potential for growth.
  • Abbott Laboratories reported earnings per share (EPS) of $1.09 for the latest quarter, exceeding analysts' expectations, which demonstrates the company's strong financial health and ability to generate profit.
  • The company has a solid return on equity of 20.74%, indicating effective management and a strong ability to generate returns for shareholders.

Cons of Abbott Laboratories

  • The company had revenue of $10.36 billion for the latest quarter, which was slightly below analysts' expectations, indicating potential challenges in meeting market forecasts.
  • Insider selling activity, such as the recent sale of 2,600 shares by a director, may raise concerns about the company's future prospects and insider confidence.
  • Despite a strong financial performance, the stock has seen fluctuations, with a 1-year low of $99.71, which could indicate volatility and risk for investors.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$234.67 billion
P/E Ratio
17.63
Consensus Rating
Moderate Buy
Consensus Price Target
$142.59 (+5.7% Upside)
Volume
4.10 million shares
Average Volume
6.10 million shares
Today's Range
$132.93
$135.35
50-Day Range
$123.63
$135.52
52-Week Range
$99.71
$141.23
Dividend Yield
1.76%
AstraZeneca stock logo

8. AstraZeneca NASDAQ:AZN

$73.74 -0.09 (-0.12%)
Closing price 04:00 PM Eastern
Extended Trading
$73.35 -0.39 (-0.53%)
As of 05:24 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. More about AstraZeneca

Pros of AstraZeneca

  • AstraZeneca has demonstrated strong financial performance with a recent revenue of approximately $13.59 billion, indicating a year-over-year growth of 7.2%, which reflects the company's ability to expand its market presence.
  • The company boasts a high return on equity of 32.23%, suggesting effective management and profitability in generating returns for shareholders.
  • Analysts have a consensus rating of "Buy" for AstraZeneca, with an average target price of around $85.00, indicating positive market sentiment and potential for stock appreciation.

Cons of AstraZeneca

  • The company's recent revenue fell short of analysts' expectations, which could raise concerns about its ability to meet future growth targets.
  • Despite positive growth, the competitive landscape in the biopharmaceutical industry is intense, which may impact AstraZeneca's market share and pricing power.
  • One analyst has rated the stock with a hold rating, suggesting that there may be uncertainty regarding its short-term performance.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$228.69 billion
P/E Ratio
32.63
Consensus Rating
Buy
Consensus Price Target
$85.00 (+15.3% Upside)
Volume
3.55 million shares
Average Volume
5.58 million shares
Today's Range
$73.43
$74.16
50-Day Range
$64.87
$73.83
52-Week Range
$61.24
$87.68
Dividend Yield
2.85%
Merck & Co., Inc. stock logo

9. Merck & Co., Inc. NYSE:MRK

$80.26 -1.09 (-1.33%)
Closing price 03:59 PM Eastern
Extended Trading
$80.08 -0.19 (-0.24%)
As of 05:24 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Merck & Co, Inc is a health care company, which engages in the provision of health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products. More about Merck & Co., Inc.

Pros of Merck & Co., Inc.

  • The current stock price is around $82, reflecting a stable position in the market.
  • Merck recently reported earnings per share of $2.22, exceeding analyst expectations, indicating strong financial performance.
  • The company has a solid dividend yield of approximately 4.10%, providing a reliable income stream for investors.

Cons of Merck & Co., Inc.

  • Merck's revenue for the latest quarter was down 1.6% year-over-year, which may raise concerns about growth sustainability.
  • Some analysts have downgraded their ratings, with Citigroup lowering its target price significantly, indicating potential volatility.
  • Insider selling activity has been noted, with a senior vice president selling shares, which could signal lack of confidence in the stock's future performance.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$201.55 billion
P/E Ratio
11.93
Consensus Rating
Hold
Consensus Price Target
$109.19 (+36.0% Upside)
Volume
11.80 million shares
Average Volume
12.78 million shares
Today's Range
$79.98
$81.68
50-Day Range
$73.46
$85.23
52-Week Range
$73.31
$134.63
Dividend Yield
4.17%
Intuitive Surgical stock logo

10. Intuitive Surgical NASDAQ:ISRG

$522.41 -7.19 (-1.36%)
Closing price 04:00 PM Eastern
Extended Trading
$521.52 -0.88 (-0.17%)
As of 05:23 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Intuitive Surgical, Inc develops, manufactures, and markets products that enable physicians and healthcare providers to enhance the quality of and access to minimally invasive care in the United States and internationally. More about Intuitive Surgical

Pros of Intuitive Surgical

  • The current stock price is around $521, which reflects a strong market position and potential for growth.
  • Intuitive Surgical, Inc. reported earnings per share of $1.81, exceeding analysts' expectations, indicating robust financial performance.
  • The company has a high net margin of approximately 27.81%, suggesting efficient operations and profitability.

Cons of Intuitive Surgical

  • The P/E ratio is around 82, which may indicate that the stock is overvalued compared to its earnings, suggesting potential risk for investors.
  • Insider selling has been notable, with executives selling a significant number of shares, which could signal a lack of confidence in the company's future performance.
  • The stock has shown volatility with a beta of 1.67, indicating that it is more volatile than the market, which could lead to higher risk for investors.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$187.24 billion
P/E Ratio
81.50
Consensus Rating
Moderate Buy
Consensus Price Target
$588.95 (+12.7% Upside)
Volume
1.68 million shares
Average Volume
2.03 million shares
Today's Range
$521.50
$529.34
50-Day Range
$451.58
$565.94
52-Week Range
$413.82
$616.00
Dividend Yield
N/A
Amgen stock logo

11. Amgen NASDAQ:AMGN

$291.81 -1.62 (-0.55%)
Closing price 04:00 PM Eastern
Extended Trading
$290.88 -0.94 (-0.32%)
As of 05:24 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout. More about Amgen

Pros of Amgen

  • The current stock price is around $293, reflecting a recent increase, which may indicate positive market sentiment towards the company.
  • Amgen Inc. reported a significant earnings per share (EPS) of $4.90 for the latest quarter, surpassing analysts' expectations, which suggests strong financial performance.
  • The company has shown a year-over-year revenue growth of 9.4%, indicating a robust business model and increasing demand for its products.

Cons of Amgen

  • The company has a relatively high price-to-earnings (P/E) ratio of 38.86, which may indicate that the stock is overvalued compared to its earnings, potentially leading to a price correction.
  • Amgen Inc. has a debt-to-equity ratio of 9.62, suggesting a high level of debt relative to equity, which could pose risks in times of economic downturns or rising interest rates.
  • Recent analyst ratings show a mix of opinions, with several analysts downgrading their ratings, which may reflect concerns about the company's future performance.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$156.91 billion
P/E Ratio
38.65
Consensus Rating
Hold
Consensus Price Target
$309.22 (+6.0% Upside)
Volume
1.83 million shares
Average Volume
2.81 million shares
Today's Range
$291.15
$294.67
50-Day Range
$262.28
$295.30
52-Week Range
$253.30
$346.85
Dividend Yield
3.32%
Thermo Fisher Scientific stock logo

12. Thermo Fisher Scientific NYSE:TMO

$415.25 +0.71 (+0.17%)
Closing price 03:59 PM Eastern
Extended Trading
$415.24 -0.01 (0.00%)
As of 05:21 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. More about Thermo Fisher Scientific

Pros of Thermo Fisher Scientific

  • The company recently reported earnings per share (EPS) of $5.15, exceeding analyst expectations, which indicates strong financial performance and potential for future growth.
  • Thermo Fisher Scientific Inc. has a solid return on equity of 17.51%, suggesting effective management and profitability relative to shareholder equity.
  • The current stock price is around $429.93, which reflects a stable valuation in the market, making it an attractive option for investors looking for growth in the medical research sector.

Cons of Thermo Fisher Scientific

  • Despite recent growth, the company's revenue increased only by 0.2% year-over-year, which may raise concerns about its ability to sustain growth in a competitive market.
  • Several analysts have recently downgraded their price targets for the stock, indicating a lack of confidence in short-term performance.
  • The payout ratio is currently at 10.09%, which, while sustainable, may limit the company's ability to increase dividends in the future if earnings do not grow significantly.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$156.76 billion
P/E Ratio
25.12
Consensus Rating
Moderate Buy
Consensus Price Target
$605.30 (+45.8% Upside)
Volume
3.04 million shares
Average Volume
1.92 million shares
Today's Range
$413.28
$424.51
50-Day Range
$393.53
$452.24
52-Week Range
$390.50
$627.88
Dividend Yield
0.43%
Boston Scientific stock logo

13. Boston Scientific NYSE:BSX

$99.38 +0.04 (+0.04%)
Closing price 03:59 PM Eastern
Extended Trading
$99.61 +0.23 (+0.24%)
As of 05:25 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. More about Boston Scientific

Pros of Boston Scientific

  • The company recently reported strong quarterly earnings, exceeding analysts' expectations with a revenue of $4.66 billion, indicating robust growth and demand for its medical devices.
  • Boston Scientific Co. has a solid return on equity of 17.80%, suggesting effective management and profitability, which can be attractive to investors looking for stable returns.
  • The current stock price is around $100.05, which is near its 52-week high of $107.17, reflecting positive market sentiment and potential for further appreciation.

Cons of Boston Scientific

  • Insider selling has been significant, with executives selling over 411,970 shares recently, which may signal a lack of confidence in the stock's short-term performance.
  • The stock has a high price-to-earnings (P/E) ratio of 80.04, suggesting that it may be overvalued compared to its earnings, which could deter value-focused investors.
  • Despite recent growth, the company faces intense competition in the medical device market, which could impact its market share and profitability in the future.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$147.03 billion
P/E Ratio
79.50
Consensus Rating
Buy
Consensus Price Target
$116.00 (+16.7% Upside)
Volume
8.45 million shares
Average Volume
6.50 million shares
Today's Range
$98.78
$100.08
50-Day Range
$89.78
$106.61
52-Week Range
$71.88
$107.17
Dividend Yield
N/A
Danaher stock logo

14. Danaher NYSE:DHR

$204.62 +2.00 (+0.98%)
Closing price 03:59 PM Eastern
Extended Trading
$201.69 -2.93 (-1.43%)
As of 05:24 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. More about Danaher

Pros of Danaher

  • The current stock price is around $191, which may present a buying opportunity for investors looking for growth in the healthcare and industrial sectors.
  • Danaher Co. reported strong quarterly earnings, with earnings per share of $1.88, exceeding expectations, indicating robust financial health and operational efficiency.
  • The company has a solid market capitalization of approximately $144.36 billion, reflecting its significant presence and stability in the market.

Cons of Danaher

  • The price-to-earnings (P/E) ratio of 38.17 suggests that the stock may be overvalued compared to its earnings, which could deter value-focused investors.
  • Danaher Co. has a price-to-earnings-growth (PEG) ratio of 2.66, indicating that the stock's price may not be justified by its earnings growth rate, which could signal potential overvaluation.
  • The company's beta of 0.77 indicates lower volatility compared to the market, which may not appeal to investors seeking high-risk, high-reward opportunities.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$146.44 billion
P/E Ratio
38.75
Consensus Rating
Moderate Buy
Consensus Price Target
$248.17 (+21.3% Upside)
Volume
4.29 million shares
Average Volume
3.49 million shares
Today's Range
$202.67
$207.00
50-Day Range
$173.85
$202.63
52-Week Range
$171.00
$281.70
Dividend Yield
0.67%
Stryker stock logo

15. Stryker NYSE:SYK

$381.03 -4.02 (-1.04%)
Closing price 03:59 PM Eastern
Extended Trading
$381.08 +0.06 (+0.02%)
As of 04:20 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. More about Stryker

Pros of Stryker

  • The current stock price is around $382, reflecting a strong market position and investor interest in the medical technology sector.
  • Stryker Co. reported a revenue increase of approximately 11.9% compared to the same quarter last year, indicating robust growth and demand for its products.
  • The company has a solid net margin of 13.25%, showcasing its ability to maintain profitability while managing costs effectively.

Cons of Stryker

  • The price-to-earnings ratio is relatively high at 49.26, which may indicate that the stock is overvalued compared to its earnings.
  • Insider selling has occurred, with a director selling 200,000 shares, which could signal a lack of confidence in the company's short-term performance.
  • The stock has experienced fluctuations, with a 1-year low of $314.93 and a high of $406.19, indicating potential volatility that could affect investment stability.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$145.43 billion
P/E Ratio
49.10
Consensus Rating
Moderate Buy
Consensus Price Target
$427.30 (+12.1% Upside)
Volume
792,321 shares
Average Volume
1.33 million shares
Today's Range
$379.80
$385.42
50-Day Range
$336.96
$394.63
52-Week Range
$314.93
$406.19
Dividend Yield
0.88%
Pfizer stock logo

16. Pfizer NYSE:PFE

$24.46 +0.16 (+0.64%)
Closing price 03:59 PM Eastern
Extended Trading
$24.32 -0.13 (-0.53%)
As of 05:24 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. More about Pfizer

Pros of Pfizer

  • The current stock price is around $24, which may present a buying opportunity for investors looking for value in the biopharmaceutical sector.
  • Pfizer Inc. has recently reported strong earnings, exceeding analysts' expectations, which indicates robust financial health and operational efficiency.
  • The company has a solid dividend yield of approximately 7.08%, providing a steady income stream for investors.

Cons of Pfizer

  • The company has experienced a year-over-year revenue decline, which may raise concerns about its growth prospects.
  • Pfizer Inc. has a high payout ratio of 124.64%, suggesting that it may be returning more to shareholders than it is earning, which could be unsustainable.
  • Market volatility and economic uncertainties could impact the stock's performance, making it a riskier investment in the current climate.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$139.04 billion
P/E Ratio
17.34
Consensus Rating
Moderate Buy
Consensus Price Target
$29.17 (+19.3% Upside)
Volume
38.49 million shares
Average Volume
41.03 million shares
Today's Range
$24.32
$24.69
50-Day Range
$21.57
$24.41
52-Week Range
$20.92
$31.54
Dividend Yield
7.44%
Gilead Sciences stock logo

17. Gilead Sciences NASDAQ:GILD

$109.30 -0.79 (-0.72%)
Closing price 04:00 PM Eastern
Extended Trading
$109.25 -0.05 (-0.05%)
As of 05:24 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. More about Gilead Sciences

Pros of Gilead Sciences

  • The stock has received multiple upgrades from analysts, indicating strong confidence in its future performance. Recent upgrades include a target price increase to $135.00, suggesting potential for growth.
  • Gilead Sciences, Inc. has a current stock price around $110, which reflects a solid position in the market and may present a good entry point for investors.
  • The company has a moderate buy consensus rating from analysts, with a significant number of buy ratings, indicating positive sentiment among market experts.

Cons of Gilead Sciences

  • Corporate insiders own only 0.27% of the company's stock, which may indicate a lack of confidence in the company's future performance from those who know it best.
  • Recent insider sales, including significant transactions by the CFO and CEO, could raise concerns about the company's short-term outlook and the executives' confidence in its performance.
  • The dividend payout ratio is relatively high at 66.53%, which may limit the company's ability to reinvest in growth opportunities or respond to market changes.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$135.96 billion
P/E Ratio
295.41
Consensus Rating
Moderate Buy
Consensus Price Target
$110.55 (+1.1% Upside)
Volume
6.41 million shares
Average Volume
7.73 million shares
Today's Range
$109.02
$111.04
50-Day Range
$96.86
$113.00
52-Week Range
$62.69
$119.96
Dividend Yield
2.86%
Sanofi stock logo

18. Sanofi NASDAQ:SNY

$49.70 -0.18 (-0.36%)
Closing price 04:00 PM Eastern
Extended Trading
$49.85 +0.15 (+0.30%)
As of 05:13 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. More about Sanofi

Pros of Sanofi

  • Sanofi has received multiple positive ratings from analysts, including a recent "strong-buy" rating, indicating strong confidence in the stock's potential for growth.
  • The current stock price is around $52, which is below the average target price of approximately $63.33, suggesting potential for price appreciation.
  • Sanofi recently reported earnings that exceeded analysts' expectations, showcasing its ability to generate revenue and profit, which can be a positive indicator for future performance.

Cons of Sanofi

  • Sanofi's revenue has decreased by 11% year-over-year, which may raise concerns about its growth prospects and ability to maintain profitability.
  • The stock has experienced volatility, with recent trading showing a decline to around $49.40, which could indicate market uncertainty.
  • Despite positive earnings, the company has a relatively high price-to-earnings (P/E) ratio, which may suggest that the stock is overvalued compared to its earnings.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$121.89 billion
P/E Ratio
19.96
Consensus Rating
Buy
Consensus Price Target
$61.50 (+23.7% Upside)
Volume
1.58 million shares
Average Volume
2.40 million shares
Today's Range
$49.60
$50.06
50-Day Range
$49.19
$55.44
52-Week Range
$45.80
$60.12
Dividend Yield
3.23%
Vertex Pharmaceuticals stock logo

19. Vertex Pharmaceuticals NASDAQ:VRTX

$452.44 +0.92 (+0.20%)
Closing price 04:00 PM Eastern
Extended Trading
$447.60 -4.84 (-1.07%)
As of 05:23 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). More about Vertex Pharmaceuticals

Pros of Vertex Pharmaceuticals

  • The current stock price is around $446, which may present a buying opportunity for investors looking for growth in the biotechnology sector.
  • Vertex Pharmaceuticals has received multiple recent upgrades from analysts, indicating positive sentiment and potential for stock appreciation.
  • The company reported a year-over-year revenue increase of 2.6%, showcasing its ability to grow despite market challenges.

Cons of Vertex Pharmaceuticals

  • The company recently missed earnings expectations, reporting $4.06 EPS compared to the consensus estimate of $4.29, which may raise concerns about its profitability.
  • Vertex Pharmaceuticals has a negative return on equity of 2.02%, indicating that the company is not generating profit from its equity, which could deter potential investors.
  • The stock has a high price-to-earnings ratio, suggesting that it may be overvalued compared to its earnings, which could lead to price corrections.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$116.19 billion
P/E Ratio
-205.65
Consensus Rating
Moderate Buy
Consensus Price Target
$515.04 (+13.8% Upside)
Volume
1.02 million shares
Average Volume
1.42 million shares
Today's Range
$450.13
$460.33
50-Day Range
$421.16
$509.50
52-Week Range
$377.85
$519.88
Dividend Yield
N/A
Medtronic stock logo

20. Medtronic NYSE:MDT

$88.01 +0.05 (+0.06%)
Closing price 03:59 PM Eastern
Extended Trading
$88.06 +0.05 (+0.06%)
As of 05:24 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Medtronic plc develops, manufactures, and sells device-based medical therapies to healthcare systems, physicians, clinicians, and patients worldwide. More about Medtronic

Pros of Medtronic

  • The current stock price is around $88.48, which is positioned between its 12-month low and high, indicating potential for growth.
  • Medtronic plc recently reported earnings that exceeded analysts' expectations, showcasing strong financial performance with a revenue increase of 3.9% year-over-year.
  • The company has a solid return on equity of 14.07%, reflecting effective management and profitability, which can be attractive to investors looking for stable returns.

Cons of Medtronic

  • Despite recent earnings growth, the stock has seen price target reductions from several analysts, indicating potential concerns about future performance.
  • The company's payout ratio is relatively high at 78.45%, which may raise concerns about sustainability in dividend payments if earnings do not continue to grow.
  • Medtronic plc operates in a highly competitive medical technology market, which can pose risks to maintaining market share and profitability.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$112.88 billion
P/E Ratio
26.75
Consensus Rating
Moderate Buy
Consensus Price Target
$97.00 (+10.2% Upside)
Volume
4.64 million shares
Average Volume
6.87 million shares
Today's Range
$87.76
$88.47
50-Day Range
$80.70
$87.92
52-Week Range
$75.96
$96.25
Dividend Yield
3.22%
Bristol-Myers Squibb stock logo

21. Bristol-Myers Squibb NYSE:BMY

$50.13 +0.16 (+0.32%)
Closing price 03:59 PM Eastern
Extended Trading
$50.16 +0.03 (+0.06%)
As of 05:24 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. More about Bristol-Myers Squibb

Pros of Bristol-Myers Squibb

  • The current stock price is around $48.95, which may present a buying opportunity for investors looking for value in the biopharmaceutical sector.
  • Bristol-Myers Squibb has a diverse portfolio of products, including recent advancements in treatments for various cancers and autoimmune diseases, which can drive future revenue growth.
  • The company reported a quarterly revenue of $11.20 billion, exceeding analyst expectations, indicating strong market performance and demand for its products.

Cons of Bristol-Myers Squibb

  • The company has experienced a negative net margin of 18.53%, which may raise concerns about profitability and operational efficiency.
  • Recent price target reductions by analysts, including a drop from $67.00 to $55.00, indicate a cautious outlook on the stock's performance.
  • With a debt-to-equity ratio of 2.90, Bristol-Myers Squibb carries a significant amount of debt, which could pose risks in times of economic downturns or rising interest rates.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$102.01 billion
P/E Ratio
-11.34
Consensus Rating
Hold
Consensus Price Target
$58.00 (+15.7% Upside)
Volume
10.97 million shares
Average Volume
13.03 million shares
Today's Range
$49.86
$50.76
50-Day Range
$44.06
$55.32
52-Week Range
$39.35
$63.33
Dividend Yield
5.18%
McKesson stock logo

22. McKesson NYSE:MCK

$716.75 +11.89 (+1.69%)
Closing price 03:59 PM Eastern
Extended Trading
$715.00 -1.75 (-0.24%)
As of 05:19 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

McKesson Corporation provides healthcare services in the United States and internationally. It operates through four segments: U.S. More about McKesson

Pros of McKesson

  • The current stock price is around $713, reflecting a stable market position and potential for growth.
  • McKesson Co. has a strong institutional ownership, with over 85% of its stock held by institutional investors, indicating confidence from large financial entities.
  • The company recently announced a quarterly dividend of $0.71 per share, which translates to an annualized dividend yield of approximately 0.39%, providing a steady income stream for investors.

Cons of McKesson

  • Despite recent upgrades, the stock has shown fluctuations, with a 1-year low of around $464.42, indicating potential volatility.
  • Insider selling has been notable, with executives selling over 13,000 shares recently, which may signal a lack of confidence in the stock's short-term performance.
  • The company's P/E ratio is approximately 32.65, which may be considered high, suggesting that the stock could be overvalued compared to its earnings.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$89.67 billion
P/E Ratio
32.82
Consensus Rating
Moderate Buy
Consensus Price Target
$694.38 (-3.1% Downside)
Volume
782,835 shares
Average Volume
917,909 shares
Today's Range
$706.04
$717.76
50-Day Range
$652.88
$726.05
52-Week Range
$464.42
$731.00
Dividend Yield
0.40%
HCA Healthcare stock logo

23. HCA Healthcare NYSE:HCA

$367.19 +2.27 (+0.62%)
Closing price 03:59 PM Eastern
Extended Trading
$367.64 +0.45 (+0.12%)
As of 04:43 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

HCA Healthcare, Inc, through its subsidiaries, owns and operates hospitals and related healthcare entities in the United States. More about HCA Healthcare

Pros of HCA Healthcare

  • The current stock price is around $381, reflecting a strong performance in the healthcare sector.
  • HCA Healthcare, Inc. reported earnings per share of $6.45, significantly exceeding analysts' expectations, indicating robust financial health.
  • The company has shown a year-over-year revenue increase of 5.7%, suggesting consistent growth and demand for its services.

Cons of HCA Healthcare

  • The stock has a relatively high debt-to-equity ratio of 69.07, which may indicate financial risk and reliance on borrowed funds.
  • Recent analyst ratings show mixed opinions, with some downgrades, which could signal uncertainty in the stock's future performance.
  • The company's payout ratio is 12.81%, which, while sustainable, may limit future dividend growth potential.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$88.34 billion
P/E Ratio
16.71
Consensus Rating
Moderate Buy
Consensus Price Target
$392.47 (+6.9% Upside)
Volume
1.03 million shares
Average Volume
1.45 million shares
Today's Range
$363.95
$370.51
50-Day Range
$317.93
$387.49
52-Week Range
$289.98
$417.14
Dividend Yield
0.77%
Elevance Health stock logo

24. Elevance Health NYSE:ELV

$380.65 -3.27 (-0.85%)
Closing price 03:59 PM Eastern
Extended Trading
$382.85 +2.20 (+0.58%)
As of 05:05 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Elevance Health, Inc., together with its subsidiaries, operates as a health benefits company in the United States. The company operates through four segments: Health Benefits, CarelonRx, Carelon Services, and Corporate & Other. It offers a variety of health plans and services to program members; health products; an array of fee-based administrative managed care services; and specialty and other insurance products and services, such as stop loss, dental, vision, life, disability, and supplemental health insurance benefits. The company operates in the pharmacy services business; and markets and offers pharmacy services, including pharmacy benefit management, as well as home delivery and specialty pharmacies, claims adjudication, formulary management, pharmacy networks, rebate administration, a prescription drug database, and member services. In addition, it provides healthcare-related services and capabilities, including utilization management, behavioral health, integrated care delivery, palliative care, payment integrity services, subrogation services, and health and wellness programs, as well as services related to data management, information technology, and business operations. Further, the company is involved in the National Government Services business. The company provides its services under the Anthem Blue Cross and Blue Shield, Wellpoint, and Carelon brand names. The company was formerly known as Anthem, Inc. and changed its name to Elevance Health, Inc. in June 2022. Elevance Health, Inc. was incorporated in 2001 and is headquartered in Indianapolis, Indiana.

Market Capitalization
$86.00 billion
P/E Ratio
14.86
Consensus Rating
Moderate Buy
Consensus Price Target
$498.87 (+31.1% Upside)
Volume
1.25 million shares
Average Volume
1.55 million shares
Today's Range
$380.45
$385.87
50-Day Range
$372.33
$441.02
52-Week Range
$357.45
$567.26
Dividend Yield
1.78%
GSK stock logo

25. GSK NYSE:GSK

$41.58 +0.29 (+0.69%)
Closing price 03:59 PM Eastern
Extended Trading
$41.21 -0.38 (-0.90%)
As of 05:24 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. More about GSK

Pros of GSK

  • The current stock price is around $41, reflecting a recent increase, which may indicate positive market sentiment towards GSK plc.
  • Institutional investors have shown renewed interest, with several hedge funds acquiring significant stakes in GSK plc during the recent quarter, suggesting confidence in the company's future performance.
  • GSK plc has a solid market capitalization of approximately $84.65 billion, indicating a strong position in the pharmaceutical industry.

Cons of GSK

  • Recent downgrades from analysts, including a "strong sell" rating from HSBC Global Research, may signal concerns about the company's short-term performance.
  • Deutsche Bank AG significantly reduced its holdings in GSK plc by 99%, which could indicate a lack of confidence in the stock's future prospects.
  • The company has a debt-to-equity ratio of 1.12, which suggests that GSK plc has a higher level of debt compared to its equity, potentially increasing financial risk.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$85.23 billion
P/E Ratio
26.15
Consensus Rating
Hold
Consensus Price Target
$37.38 (-10.1% Downside)
Volume
4.49 million shares
Average Volume
4.83 million shares
Today's Range
$41.32
$41.76
50-Day Range
$33.65
$41.63
52-Week Range
$31.72
$44.67
Dividend Yield
4.10%
CVS Health stock logo

26. CVS Health NYSE:CVS

$65.71 +1.45 (+2.26%)
Closing price 03:59 PM Eastern
Extended Trading
$65.34 -0.37 (-0.56%)
As of 05:25 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

CVS Health Corporation provides health solutions in the United States. It operates through Health Care Benefits, Health Services, and Pharmacy & Consumer Wellness segments. More about CVS Health

Pros of CVS Health

  • CVS Health Co. recently reported strong quarterly earnings, with earnings per share (EPS) of $2.25, significantly exceeding the consensus estimate, indicating robust financial performance.
  • The company has shown a year-over-year revenue increase of 7.0%, reflecting its growth potential and ability to expand its market share in the health solutions sector.
  • CVS Health Co. has a current stock price around $63.61, which may present a buying opportunity for investors looking for value in the healthcare sector.

Cons of CVS Health

  • The company has a relatively low net margin of 1.24%, which may indicate challenges in profitability compared to competitors in the healthcare industry.
  • CVS Health Co. has a debt-to-equity ratio of 0.80, suggesting that the company is somewhat reliant on debt financing, which could pose risks if interest rates rise or if the company faces financial difficulties.
  • Despite recent positive earnings, the stock has experienced volatility, with a one-year high of $72.51 and a low of $43.56, indicating potential risks for investors concerned about price fluctuations.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$83.12 billion
P/E Ratio
17.95
Consensus Rating
Moderate Buy
Consensus Price Target
$75.07 (+14.2% Upside)
Volume
7.42 million shares
Average Volume
11.02 million shares
Today's Range
$64.11
$65.75
50-Day Range
$60.03
$70.40
52-Week Range
$43.56
$72.51
Dividend Yield
4.22%
The Cigna Group stock logo

27. The Cigna Group NYSE:CI

$309.99 -3.63 (-1.16%)
Closing price 03:59 PM Eastern
Extended Trading
$312.80 +2.81 (+0.91%)
As of 05:20 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

The Cigna Group, together with its subsidiaries, provides insurance and related products and services in the United States. More about The Cigna Group

Pros of The Cigna Group

  • The Cigna Group recently reported strong quarterly earnings, exceeding analysts' expectations with earnings per share significantly higher than consensus estimates, indicating robust financial performance.
  • The current stock price is around $311, reflecting a solid market position and potential for growth, especially given the company's recent revenue increase of over 14% year-over-year.
  • The company has a healthy return on equity of 18.61%, suggesting effective management and profitability, which can be attractive to investors looking for strong financial metrics.

Cons of The Cigna Group

  • The stock has experienced fluctuations, with a 12-month high of $370.83 and a low of $262.03, which may indicate volatility and risk for potential investors.
  • Insider selling has occurred, with a director recently selling a significant number of shares, which could raise concerns about the company's future outlook from those within the organization.
  • The net margin is relatively low at 1.39%, suggesting that while the company generates substantial revenue, profitability may be constrained, which could affect long-term growth.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$82.81 billion
P/E Ratio
25.33
Consensus Rating
Moderate Buy
Consensus Price Target
$380.39 (+22.7% Upside)
Volume
2.21 million shares
Average Volume
1.71 million shares
Today's Range
$309.48
$315.86
50-Day Range
$301.90
$340.21
52-Week Range
$262.03
$370.83
Dividend Yield
1.95%
Zoetis stock logo

28. Zoetis NYSE:ZTS

$166.31 -0.79 (-0.47%)
Closing price 03:59 PM Eastern
Extended Trading
$165.84 -0.47 (-0.28%)
As of 05:24 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. More about Zoetis

Pros of Zoetis

  • The current stock price is around $170, which reflects a recent increase, indicating positive market sentiment towards the company.
  • Zoetis Inc. has a consensus rating of "Buy" with a price target of approximately $212.75, suggesting potential for price appreciation.
  • The company reported strong quarterly earnings, exceeding expectations with earnings per share of $1.48, which demonstrates robust financial performance.

Cons of Zoetis

  • Insider selling activity has been noted, with executives selling shares, which may raise concerns about their confidence in the company's future performance.
  • The stock has a relatively high price-to-earnings (P/E) ratio of around 31, which could indicate that the stock is overvalued compared to its earnings.
  • Despite recent growth, the company has a debt-to-equity ratio of 1.09, suggesting a reliance on debt financing that could pose risks in a rising interest rate environment.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$74.04 billion
P/E Ratio
30.40
Consensus Rating
Buy
Consensus Price Target
$212.75 (+27.9% Upside)
Volume
2.47 million shares
Average Volume
2.54 million shares
Today's Range
$164.95
$168.05
50-Day Range
$144.09
$170.40
52-Week Range
$139.70
$200.33
Dividend Yield
1.19%
Regeneron Pharmaceuticals stock logo

29. Regeneron Pharmaceuticals NASDAQ:REGN

$518.60 -4.93 (-0.94%)
Closing price 04:00 PM Eastern
Extended Trading
$518.00 -0.60 (-0.12%)
As of 05:22 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. More about Regeneron Pharmaceuticals

Pros of Regeneron Pharmaceuticals

  • The current stock price is around $493, reflecting a recent increase of 2.1%, which may indicate positive market sentiment.
  • Regeneron Pharmaceuticals, Inc. has received multiple upgrades from analysts, including a "strong-buy" rating from Canaccord Genuity Group, suggesting strong future performance potential.
  • The company has a solid market capitalization of approximately $53.25 billion, indicating a strong position in the biopharmaceutical sector.

Cons of Regeneron Pharmaceuticals

  • The company reported earnings per share that missed consensus estimates, which may raise concerns about its short-term performance.
  • Regeneron Pharmaceuticals, Inc. has experienced a year-over-year revenue decline of approximately 3.7%, which could indicate challenges in maintaining growth.
  • Analysts have set varying price targets, with some significantly lower than the current stock price, suggesting potential volatility and uncertainty in future valuations.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$55.99 billion
P/E Ratio
13.55
Consensus Rating
Moderate Buy
Consensus Price Target
$836.48 (+61.3% Upside)
Volume
961,847 shares
Average Volume
871,325 shares
Today's Range
$516.10
$528.37
50-Day Range
$483.07
$614.79
52-Week Range
$476.49
$1,211.20
Dividend Yield
0.73%
Cencora stock logo

30. Cencora NYSE:COR

$286.34 +2.10 (+0.74%)
Closing price 03:59 PM Eastern
Extended Trading
$286.05 -0.29 (-0.10%)
As of 04:19 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Cencora, Inc sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers. More about Cencora

Pros of Cencora

  • The stock has received multiple upgrades from analysts, indicating strong confidence in its future performance. For instance, Wells Fargo upgraded the stock to "overweight" with a target price increase to $337.00.
  • Cencora, Inc. has a solid dividend yield of approximately 0.76%, which can provide a steady income stream for investors.
  • Recent insider trading activity shows executives are actively managing their positions, which can be a positive signal about the company's prospects.

Cons of Cencora

  • Insider selling activity has been noted, with executives selling a significant number of shares, which could indicate a lack of confidence in the stock's short-term performance.
  • The company's dividend payout ratio is currently at 25.52%, which, while sustainable, may limit future dividend increases if profits do not grow significantly.
  • Despite recent upgrades, the stock has experienced fluctuations, which may pose risks for investors looking for stability.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$55.50 billion
P/E Ratio
40.73
Consensus Rating
Moderate Buy
Consensus Price Target
$306.91 (+7.2% Upside)
Volume
1.17 million shares
Average Volume
1.52 million shares
Today's Range
$284.07
$288.08
50-Day Range
$273.87
$304.04
52-Week Range
$218.65
$309.35
Dividend Yield
0.76%
Becton, Dickinson and Company stock logo

31. Becton, Dickinson and Company NYSE:BDX

$172.62 -1.77 (-1.01%)
Closing price 03:59 PM Eastern
Extended Trading
$172.74 +0.12 (+0.07%)
As of 04:46 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. More about Becton, Dickinson and Company

Pros of Becton, Dickinson and Company

  • The current stock price is around $173, which may present a buying opportunity for investors looking for value in the medical instruments sector.
  • Becton, Dickinson and Company has a strong market capitalization of approximately $49.72 billion, indicating a solid position in the industry and potential for growth.
  • The company has a relatively low beta of 0.25, suggesting that its stock is less volatile compared to the overall market, which can be appealing for risk-averse investors.

Cons of Becton, Dickinson and Company

  • Recent price target reductions by analysts, including Barclays lowering its target from $261 to $241, may indicate a bearish outlook on the stock's short-term performance.
  • Several analysts have downgraded their ratings on the stock, with Piper Sandler moving from "overweight" to "neutral," which could signal a lack of confidence in the company's growth prospects.
  • The stock has experienced a significant decline from its 12-month high of $251.99, which may raise concerns about its ability to recover and grow in the near future.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$49.48 billion
P/E Ratio
28.68
Consensus Rating
Hold
Consensus Price Target
$219.22 (+27.0% Upside)
Volume
2.36 million shares
Average Volume
1.96 million shares
Today's Range
$171.91
$175.86
50-Day Range
$165.13
$209.57
52-Week Range
$163.33
$251.99
Dividend Yield
2.40%
Haleon stock logo

32. Haleon NYSE:HLN

$10.90 +0.02 (+0.14%)
Closing price 03:59 PM Eastern
Extended Trading
$10.92 +0.02 (+0.18%)
As of 05:24 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Haleon plc, together with its subsidiaries, engages in the research, development, manufacture, and sale of various consumer healthcare products in North America, Europe, the Middle East, Africa, Latin America, and the Asia Pacific. More about Haleon

Pros of Haleon

  • The current stock price is around $11.06, which is near its 52-week high, indicating strong market performance.
  • Haleon plc reported revenue of $3.54 billion in its latest quarter, surpassing analysts' expectations, which reflects robust demand for its consumer healthcare products.
  • Analysts have a consensus rating of "Moderate Buy" for Haleon plc, suggesting positive sentiment and potential for price appreciation.

Cons of Haleon

  • The stock has experienced a slight decline of about 0.4% recently, which may indicate short-term volatility.
  • Haleon plc has a relatively high price-to-earnings (P/E) ratio of 32.53, suggesting that the stock may be overvalued compared to its earnings.
  • Despite positive revenue growth, the company has a current ratio of 0.84, which indicates potential liquidity concerns in meeting short-term obligations.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$49.10 billion
P/E Ratio
32.07
Consensus Rating
Moderate Buy
Consensus Price Target
$12.33 (+13.0% Upside)
Volume
11.87 million shares
Average Volume
8.82 million shares
Today's Range
$10.90
$10.98
50-Day Range
$9.28
$11.42
52-Week Range
$8.25
$11.42
Dividend Yield
2.24%
Takeda Pharmaceutical stock logo

33. Takeda Pharmaceutical NYSE:TAK

$15.18 -0.06 (-0.36%)
Closing price 03:59 PM Eastern
Extended Trading
$15.18 0.00 (0.00%)
As of 04:15 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products in Japan and internationally. More about Takeda Pharmaceutical

Pros of Takeda Pharmaceutical

  • The current stock price is around $14.95, which may present a buying opportunity for investors looking for value in the pharmaceutical sector.
  • Recent institutional investments, such as Hudson Bay Capital Management increasing its stake by 10%, indicate growing confidence in the company's future performance.
  • Analyst ratings have improved, with Morgan Stanley upgrading Takeda Pharmaceutical from "equal weight" to "overweight," suggesting a positive outlook for the stock.

Cons of Takeda Pharmaceutical

  • The company reported earnings that missed consensus estimates, which could raise concerns about its profitability and operational efficiency.
  • Recent trading activity shows volatility, with the stock experiencing fluctuations, which may deter risk-averse investors.
  • Despite recent investments, hedge funds and institutional investors only own about 9.17% of the company's stock, indicating limited institutional confidence.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$48.32 billion
P/E Ratio
37.96
Consensus Rating
Buy
Consensus Price Target
N/A
Volume
1.90 million shares
Average Volume
1.94 million shares
Today's Range
$15.15
$15.29
50-Day Range
$13.69
$15.38
52-Week Range
$12.58
$15.43
Dividend Yield
1.78%
Veeva Systems stock logo

34. Veeva Systems NYSE:VEEV

$288.76 +4.63 (+1.63%)
Closing price 03:59 PM Eastern
Extended Trading
$288.40 -0.36 (-0.12%)
As of 04:51 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Veeva Systems Inc provides cloud-based software for the life sciences industry. It offers Veeva Commercial Cloud, a suite of software and analytics solutions, such as Veeva customer relationship management (CRM) that enable customer-facing employees at pharmaceutical and biotechnology companies; Veeva Vault PromoMats, an end-to-end content and digital asset management solution; Veeva Vault Medical that provides source of medical content across multiple channels and geographies; Veeva Crossix, an analytics platform for pharmaceutical brands; Veeva OpenData, a customer reference data solution; Veeva Link, a data application that allows link to generate real-time intelligence; and Veeva Compass includes de-identified and longitudinal patient data for the United States. More about Veeva Systems

Pros of Veeva Systems

  • The current stock price is around $285, reflecting a strong market position and investor interest in the company.
  • Veeva Systems Inc. reported a quarterly revenue of $759.04 million, exceeding analysts' expectations, indicating robust financial performance.
  • The company has a significant market capitalization of approximately $46.38 billion, showcasing its stability and growth potential in the life sciences software sector.

Cons of Veeva Systems

  • The stock has experienced a decline of about 1.7% recently, which may indicate short-term volatility and investor uncertainty.
  • Insider sales, including a senior vice president selling shares, could raise concerns about the company's future performance and insider confidence.
  • The price-to-earnings ratio is relatively high at 70.39, suggesting that the stock may be overvalued compared to its earnings, which could deter value-focused investors.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$46.98 billion
P/E Ratio
71.30
Consensus Rating
Moderate Buy
Consensus Price Target
$269.80 (-6.6% Downside)
Volume
1.71 million shares
Average Volume
1.14 million shares
Today's Range
$282.62
$288.91
50-Day Range
$209.34
$289.99
52-Week Range
$176.41
$291.68
Dividend Yield
N/A
Edwards Lifesciences stock logo

35. Edwards Lifesciences NYSE:EW

$75.47 -0.33 (-0.44%)
Closing price 03:59 PM Eastern
Extended Trading
$75.75 +0.28 (+0.37%)
As of 05:03 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. More about Edwards Lifesciences

Pros of Edwards Lifesciences

  • The current stock price is around $77.56, which may present a buying opportunity for investors looking for growth in the medical research sector.
  • Edwards Lifesciences Co. reported a strong quarterly earnings performance, exceeding analysts' expectations with earnings per share of $0.64, indicating robust financial health.
  • The company has a high return on equity of 19.40%, suggesting effective management and profitability, which can be attractive to investors.

Cons of Edwards Lifesciences

  • Insider selling has been noted, with a total of 59,012 shares sold recently, which may raise concerns about the company's future prospects from those who are closely involved.
  • The stock has experienced fluctuations, with a 52-week high of $95.25 and a low of $58.93, indicating volatility that could deter risk-averse investors.
  • Despite a strong earnings report, the price-to-earnings (P/E) ratio of 11.13 suggests that the stock may not be undervalued compared to its peers, which could limit upside potential.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$44.27 billion
P/E Ratio
10.83
Consensus Rating
Hold
Consensus Price Target
$80.20 (+6.3% Upside)
Volume
4.87 million shares
Average Volume
5.21 million shares
Today's Range
$75.30
$76.15
50-Day Range
$67.04
$78.09
52-Week Range
$58.93
$95.25
Dividend Yield
N/A
Alcon stock logo

36. Alcon NYSE:ALC

$88.61 -0.34 (-0.38%)
Closing price 03:59 PM Eastern
Extended Trading
$88.61 0.00 (0.00%)
As of 04:04 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Alcon Inc researches, develops, manufactures, distributes, and sells eye care products for eye care professionals and their patients worldwide. More about Alcon

Pros of Alcon

  • The current stock price is around $91.50, reflecting a strong performance in the market.
  • Alcon Inc. has shown a positive fifty-two week performance, indicating a growth of over 20%, which suggests strong investor confidence.
  • The company has a significant institutional ownership percentage, which often indicates that large investors believe in the company's potential for growth.

Cons of Alcon

  • There has been a recent increase in shares shorted, which could indicate growing skepticism about the company's future performance.
  • The month-to-month change in shares shorted shows a decline, which may suggest volatility in investor sentiment.
  • Despite a strong performance, the overall market conditions can be unpredictable, which may affect Alcon Inc.'s stock price.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$43.71 billion
P/E Ratio
37.87
Consensus Rating
Moderate Buy
Consensus Price Target
$106.13 (+19.8% Upside)
Volume
1.87 million shares
Average Volume
1.15 million shares
Today's Range
$88.47
$89.76
50-Day Range
$82.86
$98.39
52-Week Range
$80.48
$101.10
Dividend Yield
0.28%
IDEXX Laboratories stock logo

37. IDEXX Laboratories NASDAQ:IDXX

$524.18 -1.75 (-0.33%)
Closing price 04:00 PM Eastern
Extended Trading
$522.70 -1.48 (-0.28%)
As of 05:17 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. More about IDEXX Laboratories

Pros of IDEXX Laboratories

  • The company recently reported earnings per share of $2.96, exceeding analysts' expectations, which indicates strong financial performance and potential for growth.
  • IDEXX Laboratories, Inc. has a high return on equity of 55.82%, suggesting effective management and profitability, which can attract investors looking for efficient use of equity.
  • The current stock price is around $520, reflecting a positive market sentiment and potential for appreciation as the company continues to grow.

Cons of IDEXX Laboratories

  • Insider selling has been observed, with a director recently selling 1,260 shares, which could signal a lack of confidence in the company's short-term prospects.
  • Despite a year-over-year revenue increase of 3.6%, this growth rate may not be sufficient to meet the high expectations set by analysts, potentially leading to stock price volatility.
  • Some analysts have downgraded their ratings, indicating mixed sentiments in the market, which could lead to uncertainty among investors.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$42.16 billion
P/E Ratio
49.13
Consensus Rating
Moderate Buy
Consensus Price Target
$546.00 (+4.2% Upside)
Volume
374,026 shares
Average Volume
648,701 shares
Today's Range
$520.88
$528.38
50-Day Range
$361.04
$525.93
52-Week Range
$356.14
$530.73
Dividend Yield
N/A
Alnylam Pharmaceuticals stock logo

38. Alnylam Pharmaceuticals NASDAQ:ALNY

$298.58 -3.88 (-1.28%)
Closing price 04:00 PM Eastern
Extended Trading
$313.78 +15.20 (+5.09%)
As of 05:23 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. More about Alnylam Pharmaceuticals

Pros of Alnylam Pharmaceuticals

  • The current stock price is around $303.77, which reflects a strong performance in the biopharmaceutical sector.
  • Alnylam Pharmaceuticals, Inc. reported a quarterly revenue increase of over 20% compared to the same period last year, indicating robust growth potential.
  • Analysts have a consensus rating of "Moderate Buy" for the stock, suggesting positive sentiment and potential for price appreciation.

Cons of Alnylam Pharmaceuticals

  • The company has a negative price-to-earnings ratio, indicating that it is currently not profitable, which can be a red flag for potential investors.
  • Insider trading activity shows a significant sale of shares by the CEO, which may raise concerns about the company's future outlook.
  • Despite revenue growth, the company reported a loss per share that missed analyst expectations, which could indicate operational challenges.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$38.93 billion
P/E Ratio
-137.59
Consensus Rating
Moderate Buy
Consensus Price Target
$319.17 (+6.9% Upside)
Volume
454,786 shares
Average Volume
929,380 shares
Today's Range
$298.25
$303.85
50-Day Range
$224.32
$308.00
52-Week Range
$152.30
$313.78
Dividend Yield
N/A
ResMed stock logo

39. ResMed NYSE:RMD

$251.18 -1.48 (-0.59%)
Closing price 03:59 PM Eastern
Extended Trading
$251.42 +0.25 (+0.10%)
As of 04:52 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

ResMed Inc develops, manufactures, distributes, and markets medical devices and cloud-based software applications for the healthcare markets. More about ResMed

Pros of ResMed

  • The current stock price is around $240, which may present a buying opportunity for investors looking for growth in the healthcare sector.
  • ResMed Inc. has a solid annualized dividend of $2.12, providing a dividend yield of 0.87%, which can be attractive for income-focused investors.
  • The company has a low dividend payout ratio of 23.79%, indicating that it retains a significant portion of its earnings for reinvestment, which could support future growth.

Cons of ResMed

  • Recent insider selling, with significant shares sold by directors, may indicate a lack of confidence in the stock's short-term performance.
  • Analysts have mixed ratings, with one sell rating and several hold ratings, which could suggest uncertainty about the company's future prospects.
  • Target price adjustments by analysts, including decreases from previous highs, may reflect concerns about the company's growth trajectory.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$36.83 billion
P/E Ratio
29.65
Consensus Rating
Moderate Buy
Consensus Price Target
$259.33 (+3.2% Upside)
Volume
620,269 shares
Average Volume
1.01 million shares
Today's Range
$250.77
$254.98
50-Day Range
$204.54
$252.96
52-Week Range
$179.42
$263.05
Dividend Yield
0.84%
Cardinal Health stock logo

40. Cardinal Health NYSE:CAH

$153.34 +0.26 (+0.17%)
Closing price 03:59 PM Eastern
Extended Trading
$153.50 +0.16 (+0.10%)
As of 05:23 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Cardinal Health, Inc operates as a healthcare services and products company in the United States, Canada, Europe, Asia, and internationally. More about Cardinal Health

Pros of Cardinal Health

  • The current stock price is around $154, reflecting a strong performance in the market and indicating potential for growth.
  • Recent upgrades from multiple analysts, including a "strong buy" rating, suggest positive sentiment and confidence in the company's future performance.
  • Cardinal Health, Inc. has reported earnings per share (EPS) of $2.35, exceeding expectations, which demonstrates strong financial health and operational efficiency.

Cons of Cardinal Health

  • The company has a negative return on equity of 59.57%, which may raise concerns about its ability to generate profit from shareholders' investments.
  • Despite a recent increase in revenue, the net margin is only 0.59%, indicating that the company may face challenges in maintaining profitability.
  • Analysts have mixed ratings, with several holding a "neutral" stance, suggesting uncertainty about the stock's future performance.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$36.60 billion
P/E Ratio
28.61
Consensus Rating
Moderate Buy
Consensus Price Target
$150.57 (-1.8% Downside)
Volume
2.16 million shares
Average Volume
2.22 million shares
Today's Range
$152.06
$153.85
50-Day Range
$124.87
$155.53
52-Week Range
$93.17
$157.82
Dividend Yield
1.31%
argenx stock logo

41. argenx NASDAQ:ARGX

$574.96 -0.50 (-0.09%)
Closing price 04:00 PM Eastern
Extended Trading
$575.21 +0.25 (+0.04%)
As of 04:04 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

argenx SE, a biotechnology company, engages in the developing of various therapies for the treatment of autoimmune diseases in the United States, Japan, Europe, Middle East, Africa, and China. More about argenx

Pros of argenx

  • The current stock price is around $576, which may present a buying opportunity for investors looking for growth in the biotech sector.
  • Institutional investors own over 60% of argenx SE, indicating strong confidence from major financial players in the company's future prospects.
  • Recent analyst upgrades have set a consensus price target of approximately $709.18, suggesting potential upside for investors.

Cons of argenx

  • The stock has experienced volatility, with a twelve-month low of $361.26, which may concern risk-averse investors.
  • The price-to-earnings ratio is negative, indicating that the company is not currently profitable, which could deter some investors.
  • Recent trading activity shows a slight decline, with shares down about 0.7% recently, suggesting potential short-term weakness.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$35.11 billion
P/E Ratio
-653.36
Consensus Rating
Buy
Consensus Price Target
$709.18 (+23.3% Upside)
Volume
254,638 shares
Average Volume
323,661 shares
Today's Range
$574.60
$582.01
50-Day Range
$532.27
$656.65
52-Week Range
$374.55
$678.21
Dividend Yield
N/A
Agilent Technologies stock logo

42. Agilent Technologies NYSE:A

$119.80 -0.72 (-0.59%)
Closing price 03:59 PM Eastern
Extended Trading
$119.72 -0.08 (-0.07%)
As of 05:21 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Agilent Technologies, Inc provides application focused solutions to the life sciences, diagnostics, and applied chemical markets worldwide. More about Agilent Technologies

Pros of Agilent Technologies

  • The current stock price is around $110, which may present a buying opportunity for investors looking for value in the market.
  • Agilent Technologies, Inc. recently reported earnings that exceeded analysts' expectations, indicating strong financial performance and potential for growth.
  • The company has a solid market capitalization of approximately $31.62 billion, suggesting stability and a strong position in the industry.

Cons of Agilent Technologies

  • Recent price target reductions by analysts, including a downgrade from $160 to $155, may indicate a lack of confidence in the stock's short-term performance.
  • The stock has experienced fluctuations, with a 12-month high of $153.84 and a low of $96.43, suggesting volatility that could deter risk-averse investors.
  • Analysts have mixed ratings on the stock, with several firms lowering their price targets, which could signal uncertainty about the company's future growth prospects.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$34.03 billion
P/E Ratio
29.58
Consensus Rating
Moderate Buy
Consensus Price Target
$140.15 (+17.0% Upside)
Volume
2.65 million shares
Average Volume
1.93 million shares
Today's Range
$119.67
$122.83
50-Day Range
$98.97
$120.72
52-Week Range
$96.43
$153.84
Dividend Yield
0.85%
GE HealthCare Technologies stock logo

43. GE HealthCare Technologies NASDAQ:GEHC

$73.40 -0.52 (-0.70%)
Closing price 04:00 PM Eastern
Extended Trading
$72.95 -0.45 (-0.61%)
As of 04:49 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

GE HealthCare Technologies Inc engages in the development, manufacture, and marketing of products, services, and complementary digital solutions used in the diagnosis, treatment, and monitoring of patients in the United States, Canada, and internationally. More about GE HealthCare Technologies

Pros of GE HealthCare Technologies

  • The company recently reported strong quarterly earnings, with earnings per share (EPS) of $1.01, surpassing analyst expectations, indicating robust financial performance.
  • GE HealthCare Technologies Inc. has initiated a significant stock buyback plan, authorizing the repurchase of $1.00 billion in shares, which often signals that the company believes its stock is undervalued.
  • The current stock price is around $88, which is below the average target price set by analysts, suggesting potential for price appreciation.

Cons of GE HealthCare Technologies

  • Analysts have recently lowered their price targets for the stock, indicating a potential decrease in expected future performance.
  • The company’s net margin of 10.13% may suggest limited profitability compared to competitors, which could be a concern for investors seeking higher margins.
  • Despite the stock buyback plan, the overall market conditions and economic uncertainties could impact the company's stock performance negatively.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$33.61 billion
P/E Ratio
16.95
Consensus Rating
Moderate Buy
Consensus Price Target
$88.27 (+20.3% Upside)
Volume
3.05 million shares
Average Volume
4.08 million shares
Today's Range
$72.84
$74.16
50-Day Range
$58.75
$74.11
52-Week Range
$57.65
$94.80
Dividend Yield
0.20%
DexCom stock logo

44. DexCom NASDAQ:DXCM

$82.99 -1.83 (-2.16%)
Closing price 04:00 PM Eastern
Extended Trading
$83.22 +0.23 (+0.28%)
As of 05:24 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. More about DexCom

Pros of DexCom

  • The company reported a revenue of $1.04 billion for the latest quarter, exceeding analysts' expectations, indicating strong financial performance.
  • DexCom, Inc. has shown a year-over-year revenue growth of 12.5%, reflecting its expanding market presence and demand for its continuous glucose monitoring systems.
  • The current stock price is around $86.20, which may present a buying opportunity for investors looking to enter at a favorable price point.

Cons of DexCom

  • The company reported earnings per share of $0.32, which was slightly below analysts' consensus estimates, raising concerns about its profitability.
  • Despite revenue growth, the stock has experienced volatility, with a 52-week high of $118.80 and a low of $57.52, indicating potential risks for investors.
  • Some analysts have downgraded their price targets, which could signal a lack of confidence in the stock's short-term performance.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$32.54 billion
P/E Ratio
58.03
Consensus Rating
Moderate Buy
Consensus Price Target
$98.32 (+18.5% Upside)
Volume
3.24 million shares
Average Volume
3.98 million shares
Today's Range
$82.90
$85.49
50-Day Range
$59.83
$87.34
52-Week Range
$57.52
$118.80
Dividend Yield
N/A
Beigene stock logo

45. Beigene NASDAQ:ONC

$262.41 -1.01 (-0.38%)
As of 04:00 PM Eastern

BeOne Medicines Ltd. is a global oncology company domiciled in Switzerland that is discovering and developing innovative treatments that are more affordable and accessible to cancer patients worldwide. The firm portfolio spanning hematology and solid tumors, BeOne is expediting development of its diverse pipeline of novel therapeutics through its internal capabilities and collaborations. The company was founded by Xiao Dong Wang and John V. Oyler on October 28, 2010 and is headquartered in Basel, Switzerland.

Market Capitalization
$31.06 billion
P/E Ratio
-31.85
Consensus Rating
Buy
Consensus Price Target
$319.00 (+21.6% Upside)
Volume
282,581 shares
Average Volume
449,112 shares
Today's Range
$257.41
$264.00
50-Day Range
$206.32
$263.78
52-Week Range
$141.31
$287.88
Dividend Yield
N/A
Humana stock logo

46. Humana NYSE:HUM

$231.62 -0.36 (-0.16%)
Closing price 03:59 PM Eastern
Extended Trading
$232.32 +0.70 (+0.30%)
As of 05:24 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Humana Inc, together with its subsidiaries, provides medical and specialty insurance products in the United States. It operates through two segments, Insurance and CenterWell. More about Humana

Pros of Humana

  • The current stock price is around $232, which may present a buying opportunity for investors looking for value in the healthcare sector.
  • Humana Inc. recently reported strong quarterly earnings, with earnings per share of $11.58, exceeding analyst expectations, indicating robust financial performance.
  • The company has shown a year-over-year revenue increase of 8.4%, suggesting growth potential and a solid business model.

Cons of Humana

  • Despite recent earnings success, the stock has experienced volatility, with a 52-week high of $406.46 and a low of $212.45, indicating potential risk for investors.
  • The average target price from analysts is around $286.81, suggesting limited upside potential from the current stock price.
  • Humana Inc. has a price-to-earnings (P/E) ratio of approximately 23.41, which may be considered high compared to industry averages, potentially indicating overvaluation.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$27.95 billion
P/E Ratio
23.28
Consensus Rating
Hold
Consensus Price Target
$284.48 (+22.8% Upside)
Volume
1.29 million shares
Average Volume
1.79 million shares
Today's Range
$231.04
$237.82
50-Day Range
$224.81
$294.97
52-Week Range
$212.45
$406.46
Dividend Yield
1.56%
Centene stock logo

47. Centene NYSE:CNC

$55.22 -0.29 (-0.52%)
Closing price 03:59 PM Eastern
Extended Trading
$55.50 +0.28 (+0.50%)
As of 05:02 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Centene Corporation operates as a healthcare enterprise that provides programs and services to under-insured and uninsured families, commercial organizations, and military families in the United States. More about Centene

Pros of Centene

  • The current stock price is around $55, which presents a potential buying opportunity given its recent performance and analysts' price targets.
  • Centene Co. reported a significant increase in quarterly revenue, surpassing expectations, indicating strong business growth and demand for its services.
  • The company has a relatively low price-to-earnings (P/E) ratio, suggesting that the stock may be undervalued compared to its earnings potential, making it attractive for value investors.

Cons of Centene

  • The stock has experienced a downward adjustment in price targets from several analysts, which may indicate concerns about future performance.
  • Centene Co. has a net margin of only 2.03%, suggesting that profitability could be a concern, especially in a competitive market.
  • The company has a debt-to-equity ratio of 0.70, which, while manageable, indicates that it relies on debt financing, potentially increasing financial risk.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$27.48 billion
P/E Ratio
8.85
Consensus Rating
Moderate Buy
Consensus Price Target
$77.71 (+40.7% Upside)
Volume
3.04 million shares
Average Volume
4.89 million shares
Today's Range
$55.06
$55.94
50-Day Range
$54.80
$63.82
52-Week Range
$54.01
$80.59
Dividend Yield
N/A
IQVIA stock logo

48. IQVIA NYSE:IQV

$158.82 -0.95 (-0.59%)
Closing price 03:59 PM Eastern
Extended Trading
$160.65 +1.82 (+1.15%)
As of 04:43 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. More about IQVIA

Pros of IQVIA

  • The current stock price is around $139, which may present a buying opportunity for investors looking for value in the medical research sector.
  • IQVIA Holdings Inc. reported a strong quarterly earnings result, with earnings per share (EPS) of $2.70, exceeding analyst expectations, indicating robust financial health.
  • The company has a solid market capitalization of approximately $24.06 billion, reflecting its significant presence and stability in the industry.

Cons of IQVIA

  • The company has a relatively high debt-to-equity ratio of 2.12, which may indicate increased financial risk and reliance on borrowed funds.
  • Recent price target adjustments by analysts, including a decrease from $170 to $165, may signal concerns about future performance.
  • IQVIA's stock has experienced volatility, with a 1-year high of $252.88 and a low of $134.65, suggesting potential instability in its market value.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$27.48 billion
P/E Ratio
21.18
Consensus Rating
Moderate Buy
Consensus Price Target
$226.32 (+42.5% Upside)
Volume
2.74 million shares
Average Volume
1.61 million shares
Today's Range
$158.05
$163.79
50-Day Range
$136.96
$159.70
52-Week Range
$134.65
$252.88
Dividend Yield
N/A
BioNTech stock logo

49. BioNTech NASDAQ:BNTX

$105.46 -1.43 (-1.34%)
Closing price 04:00 PM Eastern
Extended Trading
$106.82 +1.37 (+1.29%)
As of 04:52 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. More about BioNTech

Pros of BioNTech

  • BioNTech SE recently reported earnings per share significantly above consensus estimates, indicating strong financial performance and potential for growth.
  • The company has a robust pipeline of immunotherapies for cancer and infectious diseases, which could lead to future revenue growth as these products are developed and commercialized.
  • Institutional investors have shown increased interest, with several hedge funds recently acquiring new stakes, suggesting confidence in the company's future prospects.

Cons of BioNTech

  • The company has reported a decline in revenue year-over-year, which may raise concerns about its ability to maintain growth in a competitive market.
  • BioNTech SE has a negative return on equity and net margin, suggesting inefficiencies in generating profit relative to shareholder equity and overall sales.
  • Analysts forecast a negative earnings per share for the current year, indicating potential challenges ahead in achieving profitability.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$25.35 billion
P/E Ratio
-50.22
Consensus Rating
Moderate Buy
Consensus Price Target
$138.25 (+31.1% Upside)
Volume
547,501 shares
Average Volume
940,327 shares
Today's Range
$105.25
$108.36
50-Day Range
$86.65
$120.54
52-Week Range
$76.53
$131.49
Dividend Yield
N/A
Mettler-Toledo International stock logo

50. Mettler-Toledo International NYSE:MTD

$1,192.00 -24.57 (-2.02%)
Closing price 03:59 PM Eastern
Extended Trading
$1,192.08 +0.08 (+0.01%)
As of 04:20 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Mettler-Toledo International Inc manufactures and supplies precision instruments and services in the Americas, Europe, Asia, and internationally. More about Mettler-Toledo International

Pros of Mettler-Toledo International

  • The current stock price is around $1,148, which reflects a significant market presence and investor interest.
  • Mettler-Toledo International Inc. reported earnings per share of $8.19, exceeding analysts' expectations, indicating strong financial performance.
  • The company has a solid market capitalization of approximately $24 billion, suggesting stability and growth potential in the precision instruments sector.

Cons of Mettler-Toledo International

  • The company's revenue decreased by 4.6% compared to the same quarter last year, which may raise concerns about future growth prospects.
  • Mettler-Toledo International Inc. has a negative return on equity, which could indicate inefficiencies in generating profit from shareholders' investments.
  • Recent downgrades from analysts, including a shift from "buy" to "hold," suggest a cautious outlook on the stock's performance.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$24.77 billion
P/E Ratio
29.41
Consensus Rating
Hold
Consensus Price Target
$1,302.11 (+9.2% Upside)
Volume
264,462 shares
Average Volume
151,922 shares
Today's Range
$1,191.12
$1,233.69
50-Day Range
$969.01
$1,218.94
52-Week Range
$946.69
$1,546.93
Dividend Yield
N/A